Form D · Biotechnology
SeqOnce BioSciences, Inc.
Pasadena, CA · CIK 0001655808
Offering snapshot reported Nov 5, 2024 · SEC filing
- Reported sold
- $882K Offering amount: $882K
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 14, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 5, 2024 | Initial | $881,831 | No comparison | 4 | SEC filing |
| Apr 27, 2018 | Initial | $1,010,909 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528695
$626,481 of the total amount is in conversion of notes.
Source: Form D, filed Nov 5, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Angermayer | Director, Executive |
| Joseph Dunham | Director |
| Michael Giardello | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2265 E. Foothill Boulevard
Pasadena, CA, 91107
Pasadena, CA, 91107